Gene therapy for ovarian cancer fails PhIII study — sinking biotech's shares - Endpoints News

7/20/2022 12:00:00 AM2 years 9 months ago
by Amber Tong

Despite promising interim results, VBL Therapeutics’ ovarian cancer drug has ultimately flopped in a Phase III trial. The Nasdaq-listed Israeli biotech revealed that the OVAL trial of ofranergene obadenovec (also known as ofra-vec, or VB-111) did not meet the…

De­spite promis­ing in­ter­im re­sults, VBL Ther­a­peu­tics’ ovar­i­an can­cer drug has ul­ti­mate­ly flopped in a Phase III tri­al. The Nas­daq-list­ed Is­raeli biotech re­vealed that the OVAL tri­… [+1704 chars]

full article...